For instance, a GEMM created to induce a glioma-like tumor with a constitutively active PIK3CA mutant could be used to evaluate whether a new PI3K inhibitor can interfere with downstream signaling of the pathway and cross an intact and/or partially disrupted (mouse) BBB. Here, PIK3CA is linked to neoplasm.